| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1997.15.1.116 |
| P698 | PubMed publication ID | 8996132 |
| P50 | author | Benny Chung-Ying Zee | Q43243040 |
| P2093 | author name string | J Latreille | |
| D Warr | |||
| L Kaizer | |||
| D Osoba | |||
| J Pater | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Canada | Q16 |
| quality of life | Q13100823 | ||
| P304 | page(s) | 116-123 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. | |
| P478 | volume | 15 |
| Q37245902 | A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. |
| Q38689927 | A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer |
| Q48282913 | A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer |
| Q40126451 | A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan |
| Q48363175 | A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. |
| Q37111164 | A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy |
| Q48224077 | A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer |
| Q49830880 | A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopo |
| Q37190499 | A review of patient self-report tools for chemotherapy-induced nausea and vomiting |
| Q35871611 | Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice |
| Q33181781 | Advances in use of the 5-HT3 receptor antagonists |
| Q33834310 | Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics |
| Q30992721 | Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran |
| Q47135544 | Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. |
| Q42642028 | Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. |
| Q34626554 | Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study |
| Q34572539 | Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings |
| Q64916595 | Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists. |
| Q34773714 | Control of nausea and vomiting after chemotherapy: what is the evidence? |
| Q53603113 | Current applications of health-related quality-of-life assessment in oncology. |
| Q40299605 | Distress before chemotherapy predicts delayed but not acute nausea |
| Q33994104 | Economics and health-related quality of life in antiemetic therapy: recommendations for trial design |
| Q53578107 | Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. |
| Q37606033 | Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy |
| Q90326455 | Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131) |
| Q53299571 | Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life. |
| Q61448632 | Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens |
| Q35984417 | Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. |
| Q84206278 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy |
| Q43276115 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy |
| Q85198744 | Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool |
| Q37326382 | Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting |
| Q26744323 | Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives |
| Q83782116 | Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study |
| Q36653386 | Gender aspects of treatment and drug related toxicity in medical oncology |
| Q24802757 | Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy |
| Q34472901 | Insight in the prediction of chemotherapy-induced nausea |
| Q84242048 | Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study |
| Q53379104 | Measuring chemotherapy-induced nausea and emesis. |
| Q77681536 | Nausea and emesis: still an unsolved problem in cancer patients? |
| Q48387907 | Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster |
| Q53365491 | New options and controversies in the management of chemotherapy-induced nausea and vomiting. |
| Q48251989 | Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. |
| Q34635638 | Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia |
| Q46328501 | Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy |
| Q45988785 | Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. |
| Q40710289 | Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial |
| Q91972935 | Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review |
| Q36206899 | Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. |
| Q73443219 | Post-operative nausea and vomiting in patients undergoing day-case surgery: an international, observational study |
| Q50227319 | Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea |
| Q51466468 | Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. |
| Q81273507 | Quality of life in terminal care--with special reference to age, gender and marital status |
| Q36575446 | Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting |
| Q51544100 | Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. |
| Q57483443 | Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study |
| Q39453505 | Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis |
| Q26747701 | Symptom management during and after treatment with concurrent chemoradiotherapy for oropharyngeal cancer: A review of the literature and areas for future research |
| Q48065428 | Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it. |
| Q43959318 | Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer |
| Q47778393 | Translation, validation of the EORTC esophageal cancer quality-of-life questionnaire for Japanese with esophageal squamous cell carcinoma: analysis in thoraco-laparoscopic esophagectomy versus open esophagectomy |
| Q30326186 | What has been learned from measuring health-related quality of life in clinical oncology. |
Search more.